UC DIS.CERT. 08/25 FRE/ DE000HD1JM16 /
11/19/2024 11:46:35 AM | Chg.-0.010 | Bid11/19/2024 | Ask11/19/2024 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
23.540EUR | -0.04% | 23.540 Bid Size: 30,000 |
23.550 Ask Size: 30,000 |
FRESENIUS SE+CO.KGAA... | - - | 8/22/2025 | Call |
GlobeNewswire
4/23
Transferring Biomedical Research to Patients Faster: ForTra gGmbH Announces Positive Funding Track R...
GlobeNewswire
2/23
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatm...
GlobeNewswire
9/4/2023
CIO Leadership: Generative AI and Visionary Leadership in the Enterprise Will Power the Discussion a...
GlobeNewswire
8/31/2023
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
GlobeNewswire
8/24/2023
CIO Leadership: The Steps Needed to Build a High-Performance Culture Will Power the Discussion at th...
GlobeNewswire
2/25/2022
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodia...
GlobeNewswire
1/5/2022
Oculis appoints Mr. Webb Ding as Global Chief Operating Officer and General Manager (China)
GlobeNewswire
12/31/2021
CIO Leadership: HMG Strategy, the World’s #1 Executive Leadership Network, Looks Ahead to its 15th Y...
GlobeNewswire
12/9/2021
Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surge...
GlobeNewswire
11/22/2021
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology
GlobeNewswire
11/22/2021
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology